Previous Article | Next Article 
Infection and Immunity, August 2001, p. 5031-5036, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5031-5036.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Neisseria meningitidis
Lipopolysaccharide Modulates the Specific Humoral Immune Response to
Neisserial Porins but Has No Effect on Porin-Induced
Upregulation of Costimulatory Ligand B7-2
Navneet
Bhasin,
Yu
Ho, and
Lee M.
Wetzler*
Division of Infectious Diseases, Boston
University School of Medicine and Evans Biomedical Research Center,
Boston, Massachusetts
Received 2 April 2001/Accepted 15 May 2001
 |
ABSTRACT |
The role of lipopolysaccharide (LPS) in the specific humoral
response to meningococcal porins was investigated by measuring anti-PorA or -PorB antibody levels in mice immunized with wild-type meningococcal strain H44/76 or with its recently described LPS-negative mutant. Two murine strains were used for these immunizations: C3H/HeJ,
which is LPS hyporesponsive, or C3H/HeOuJ, which is LPS responsive. A
high level of anti-PorB immunoglobulin G (IgG) response was induced in
both strains of mice immunized with either organism. The response
induced by the wild-type strain was greater in C3H/HeOuJ mice than in
C3H/HeJ mice, while the response induced by the LPS-negative mutant was
similar in the two murine strains. Additionally, the anti-PorB response
was similar in C3H/HeJ mice immunized with either bacterial strain. In
general, the anti-PorA IgG response was lower than the anti-PorB
response. These findings indicate that the presence of LPS is not
essential for the induction of an antineisserial porin humoral response
but can augment such a response. To determine whether LPS has any
effect on the B-cell-stimulatory effect of neisserial porins (essential
for the adjuvant activity of neisserial porins), B cells from both
murine strains were incubated with outer membrane complexes (OMCs)
prepared from strain H44/76 and its LPS-negative mutant. OMCs from
either meningococcal strain were able to increase the surface
expression of the costimulatory ligand B7-2 on B cells from either
murine strain. Consistent with previously reported findings, LPS does
not significantly affect the ability of neisserial porins to induce the
costimulatory ligand B7-2.
 |
INTRODUCTION |
In humans, meningococcal disease is
caused by Neisseria meningitidis belonging to a number of
capsular polysaccharide serogroups, including A, B, C, Y, and W-135.
The presently available vaccine against N. meningitidis is a
quadrivalent vaccine composed of capsular polysaccharides from
serogroups A, C, Y, and W-135 (18). This preparation does
not provide protection against serogroup B strains, which cause
approximately one-third of the total cases in the United States and 45 to 80% or more of the cases in Europe (6, 27). Capsular
polysaccharide from serogroup B strains mimics the human neuronal cell
adhesion molecule (10); hence, the use of group B capsule
in a vaccine introduces the risk of autoimmunity. Also, the group B
capsular polysaccharide is poorly immunogenic, as indicated by the
limited antibody response to the capsule seen in patients' sera after
natural infections by the strain (13). Consequently, a
number of groups are currently researching the potential of various
surface-exposed outer membrane proteins (OMPs) and lipopolysaccharide
(LPS) as vaccine candidates (1, 3, 8, 25). LPS, while
being reactogenic in the host, has been explored by Steeghs et al.
(29) for its potential as an adjuvant (when present in
trace amounts) in vaccine preparations.
The potential of neisserial porins PorA and PorB as vaccine candidates
and immune adjuvants has been explored by various investigators. Porins, which constitute about 60% of the bacterial surface proteins (4), have been shown to be immunogenic without the
addition of exogenous adjuvants (36, 39). Moreover,
neisserial porin preparations are known to augment the humoral response
to otherwise poorly immunogenic substances, e.g., peptides (20,
21), and induce T-cell-dependent immune response for normally
T-cell-independent antigens, e.g., polysaccharides (9, 11, 12,
22, 35). In addition, neisserial porins have been used as
immunologic adjuvants in a number of varied cases, including
noncovalent complexes with malarial peptides (20, 21),
group A streptococcal M protein (19), influenza virus
hemagglutinin (19), and covalent complexes with multiple
bacterial capsular polysaccharides (2, 9, 22, 35). In
addition to their use as vaccine adjuvants, the use of neisserial
porins as specific antineisserial vaccine candidates has also been
investigated (5, 36, 39). Despite these efforts, the
effect that LPS may have on the immunogenicity of the major outer
membrane porins (PorA and PorB) has never been adequately explored.
In this study we examined the role of LPS in modulating the immune
response to meningococcal PorA and PorB. Experiments were designed to
evaluate the immunogenicity of PorA and PorB by immunizing mice with
live meningococci or with purified PorA and PorB. The effect of LPS on
the humoral response to the meningococcal porins was assessed by
comparing the antiporin antibody levels in mice immunized with
meningococcal strain H44/76 and its recently isolated isogenic
LPS-negative mutant strain (28). This strain is devoid of
LPS and has amounts of OMPs similar to those possessed by the wild-type
parent (28). To further define the role of LPS in modulating the immune response to PorA and PorB, the immunizations were
done in an LPS-responsive murine strain, C3H/HeOuJ, and an LPS-hyporesponsive murine strain, C3H/HeJ (24). The role
of meningococcal LPS in modulating the potential immunostimulatory effect of PorB was evaluated by measuring the ability of outer membrane
complexes (OMCs) prepared from either the wild-type strain or its
LPS
mutant, to induce B7-2 expression in naïve
murine B cells in vitro.
 |
MATERIALS AND METHODS |
Mice.
Two isogenic strains of female mice at 6 weeks of age
were used for the study and were obtained from the Jackson Laboratory (Bar Harbor, Maine). These were the LPS-responsive strain C3H/HeOuJ and
the LPS-hyporesponsive strain C3H/HeJ. The LPS hyporesponsiveness of
C3H/HeJ mice is attributed to a defect in the cytoplasmic tail of the
LPS signal transducer TLR4 (24).
Bacteria.
N. meningitidis serogroup B strain
H44/76 (B:15:P1.7,16), originally isolated from a patient with
meningococcal bacteremia and meningitis from Norway, was used in the
study. Its recently isolated LPS-negative isogenic mutant strain was a
gift from Peter van der Ley, National Institute of Public Health and
the Environment, Bilthoven, The Netherlands (28). This
LPS-negative mutant strain is totally devoid of LPS and has amounts of
OMPs similar to those held by the wild-type parent (28).
The bacteria were grown in gonococcal liquid medium (23)
at 37°C with shaking to an optical density at 600 nm of 0.1 to 0.2. The bacteria were then washed with phosphate-buffered saline (PBS) once
and were resuspended in PBS at concentrations of 2 × 107 and 2 × 108 cells per ml.
Porins and LPS.
PorA and PorB were purified
(37) from H44/76 mutant strains H44/76
3
4
(15) and H44/76
1
4 (14), respectively.
These mutant strains allowed purification of the desired porins without contamination from other OMPs. The porins were purified by detergent extraction and column chromatography as described previously
(37). Polyacrylamide gel electrophoresis and silver
staining (30) (data not shown) demonstrated negligible
contamination by other proteins and LPS. Purified LPS from strain
H44/76 was kindly provided by Michael Apicella (University of Iowa
Medical Center, Iowa City, Iowa).
Immunization of mice.
Mice (n = 4) were
immunized subcutaneously with 2 × 106 or 2 × 107 bacteria of either the wild-type strain H44/76 or its
LPS-negative isogenic mutant in 100 µl of PBS. Control mice were
given 100 µl of PBS. The mice were immunized at days 0 and 21, and
sera were obtained every 7 days, ending on day 42. In a separate
experiment, following the same immunization regimen, mice were given 10 µg of purified PorA or PorB formed into proteosomes
(36).
ELISA.
The concentrations of anti-PorA- and
anti-PorB-specific immunoglobulin G (IgG) present in the immune and
nonimmune murine sera were determined by quantitative enzyme-linked
immunosorbent assay (ELISA) as described previously (36).
Briefly, flat-bottomed 96-well plates were coated overnight at room
temperature with 100 µl of a 2-µg/ml solution of purified PorA or
PorB in carbonate-bicarbonate buffer (pH 9.6). IgG concentrations were
measured for each individual murine serum. The ELISA plate contents
were developed by using the chromogenic substrate for alkaline
phosphatase (Sigma Diagnostics Inc., St. Louis, Mo.). The
concentrations of porin-specific IgG antibodies in serum samples were
calculated by extrapolation from standard IgG log-log-transformed
titration curves run in parallel. Anti-LPS IgG titers were determined
by performing an ELISA similar to that described above, except that the
plates were coated with 100 µl of a 10-µg/ml solution of purified
LPS in sodium barbital buffer (pH 4.6).
Preparation of OMCs.
N. meningitidis cultures
were grown to an optical density at 600 nm of 0.8. The cells were
suspended in PBS, and OMCs were prepared according to the method
described by van der Ley et al. (31). Briefly,
meningococci were inactivated at 56°C for 30 min and were lysed by
resuspending in 10 mM Tris (pH 8.0) followed by sonication. Cell debris
was removed by centrifuging at 10,000 × g. OMCs were
obtained from the supernatant by subsequent centrifugation at
50,000 × g. The OMCs were then treated with 1% sodium
laurylsarcosinate to remove cytoplasmic membrane proteins bound to the
OMCs. The protein content of the OMCs was determined by using the
bicinchoninic acid protein assay reagent (Pierce Chemical Co.) as per
the manufacturer's protocol. Bovine serum albumin was used as a standard.
In vitro stimulation of naïve B cells.
Naïve
B cells were isolated from the spleens of C3H/HeJ and C3H/HeOuJ mice
according to the standard protocol (38). Briefly, a
single-cell suspension of the spleen tissue was obtained by passing
through a fine wire mesh, followed by the lysis of red blood cells
(0.15 M Tris-buffered NH4Cl). T cells were removed by
T-cell-specific antibody-mediated complement lysis. Other nonspecific cells were removed by passage through a Sephadex G-10 column followed by a Ficoll gradient separation. The B cells, at a concentration of
5 × 106 cells/ml, were incubated for 24 h at
37°C and 5% CO2 in the presence of 10 µg of OMCs
(quantitated with respect to their protein content)/ml prepared from
either strain H44/76 or its LPS
mutant. Negative
(incubated with medium alone) and positive (incubated with purified
PorA and PorB proteins formed into proteosomes at a concentration of 10 µg/ml) controls were run in parallel. The cells were then probed with
rat anti-mouse antibodies and were conjugated with fluorescein
isothiocyanate to determine the level of cell surface expression of
B7-1 and B7-2 cell surface markers by flow cytometry analysis
(7). All the antibody conjugates for flow cytometry
analysis were obtained from Caltag Laboratories (Burlingame, Calif.).
 |
RESULTS |
Immunogenicity of strain H44/76 and its isogenic LPS-negative
mutant.
Anti-PorA, anti-PorB, and anti-LPS IgG levels were
measured by ELISA in sera from C3H/HeJ and C3H/HeOuJ mice after
immunization with meningococcal strain H44/76 or its LPS-negative
mutant. The anti-PorB IgG levels were greater in C3H/HeOuJ mice than in
in C3H/HeJ mice (Table 1). The wild-type strain H44/76 evoked an anti-PorB response about 30 to 40 times higher than that evoked by the
LPS-negative mutant strain in the C3H/HeOuJ mice (Table 1). The difference in the anti-PorB
response was, however, not as pronounced when the LPS-hyporesponsive
mice were immunized with either bacterial strain. In addition, as
elaborated in Table 1, even though the anti-PorB response was lower in
C3H/HeJ mice than in C3H/HeOuJ mice, it was still significant, reaching
a maximum concentration of about 6 µg/ml. Furthermore, the
LPS-negative bacterial strain evoked a very similar anti-PorB response
in the two murine strains. The maximum anti-PorA IgG level attained in mice sera was 2.2 µg/ml (Table 2).
Interestingly, a detectable anti-PorA response was obtained only in
mice immunized with 107 CFU of the LPS
mutant
strain per dose and was comparable in the two strains of mice.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Anti-PorB response (in µg of IgG/ml) generated against
wild-type N. meningitidis strain H44/76 and its LPS-negative
mutant in LPS-responsive C3H/HeOuJ mice and LPS-unresponsive C3H/HeJ
micea
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Anti-PorA response (µg of IgG/ml) generated against
wild-type N. meningitidis strain H44/76 and its LPS-negative
mutant in LPS-responsive C3H/HeOuJ mice and LPS-unresponsive
C3H/HeJ micea
|
|
When intact meningococci were given, PorB was more immunogenic than
PorA, as indicated by anti-PorB IgG levels that were higher
than
anti-PorA IgG levels (Tables
1 and
2). Since the anti-PorB
response of
mice might be modulated by the presence of LPS on
the bacterial surface
and by the ability of mice to immunologically
respond to LPS, anti-LPS
IgG levels were determined. An anti-LPS
IgG response was seen only in
the LPS-responsive C3H/HeOuJ mice
immunized with the higher dose
(10
7 CFU/dose) of wild-type strain H44/76 (data not shown).
No detectable
anti-LPS IgG antibodies were seen in sera from C3H/HeOuJ
mice
immunized with the LPS

bacterial strain or in the
sera from the LPS hyporesponsive strain
of mice immunized with either
bacterial
strain.
Immunogenicity of purified PorA and PorB.
As mentioned in the
preceding paragraph, both PorA and PorB were found to be immunogenic
when the mice were immunized with live cultures of N. meningitidis, albeit to different extents. Additionally,
variations seen in the IgG response due to modulation by LPS (either at
the host level or at the inoculum level) were different for the two
proteins. In order to determine if these differences were due to the
relative abundance or availability of the two proteins to the immune
system or due to their inherently different immunogenicity, mice were
immunized with purified PorA or PorB formed into proteosomes
(36) and the levels of anti-PorA and anti-PorB IgG were
determined by ELISA. Anti-PorA IgG levels were comparable to anti-PorB
IgG levels in sera from the two strains of mice, C3H/HeJ and C3H/HeOuJ,
when they were immunized with purified PorA or PorB (Table
3). However, the anti-PorA and anti-PorB IgG levels in sera from C3H/HeOuJ mice immunized with either porin were
about 10-fold higher than in sera from C3H/HeJ mice. These levels were
about twofold higher than the maximum IgG concentrations achieved
against PorB in C3H/HeOuJ mice immunized with 2 × 107
CFU of live cultures of the wild-type bacterial strain per dose. To
determine if anti-LPS IgG, which could have been generated against any
trace amounts of LPS contaminating the porin preparations, was induced,
an ELISA against purified LPS was carried out. No anti-LPS IgG
antibodies were detected in sera from either of the two mice strains
immunized with either of the purified porins (data not shown).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Anti-PorA and anti-PorB responses (in µg of IgG/ml)
generated against purified PorA and PorB in LPS-responsive
C3H/HeOuJ mice and LPS-unresponsive C3H/HeJ
micea
|
|
Immunostimulatory activity of OMCs from strain H44/76 and its
isogenic LPS-negative mutant.
PorB from N. meningitidis
is known to have immunostimulatory activity. PorB can activate B cells
and induce the surface expression of the costimulatory B7-2 molecules
(38). This effect is related to the porins' adjuvanticity
in conjugate vaccines (22). In order to determine if the
presence of LPS can modulate this function of PorB, purified splenic
naïve B cells were incubated in vitro with OMCs prepared from
either of the bacterial strains (wild-type H44/76 and its LPS-negative
mutant). The level of expression of B7-2 cell surface molecules was
determined in B cells isolated from the LPS-responsive mice strain
C3H/HeOuJ. In parallel, B cells prepared from the
LPS-hyporesponsive C3H/HeJ mice were also studied. The B cells, after
stimulation, were also probed for the presence of another costimulatory
cell surface molecule, B7-1. The expression of B7-2 on B cells from
C3H/HeJ mice was induced to similar extents by incubation with OMCs
prepared from either bacterial strain (Fig.
1A). However, B7-2 on B cells from
C3H/HeOuJ mice was induced to slightly higher levels by OMCs from the
wild-type strain H44/76 than by OMCs from the LPS
mutant
strain (Fig. 1A). The levels of B7-1 cell surface marker, however, did
not show a significant difference after stimulation with OMCs from the
two bacterial strains in B cells isolated from either murine strain
(Fig. 1B). These results are consistent with previous data presented
after use of purified porins (38), which was repeated as
control for this study. The surface expression of B7-2 on B cells from
either strain of mice, stimulated with 10 µg of purified PorB
protein/ml in the form of proteosomes, was elevated to a level similar
to that obtained after stimulation with OMCs prepared from the two
bacterial strains. Purified PorA (10 µg/ml) did not induce B7-2
surface expression to the levels induced by PorB in B cells isolated
from mice belonging to either of the two murine strains. Levels of
expression of B7-1 cell surface marker on B cells isolated from the two
murine strains remained unchanged upon stimulation by either PorA or
PorB (data not shown).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 1.
In vitro stimulation of naïve B cells from
C3H/HeOuJ mice and C3H/HeJ mice. B cells were incubated for 24 h
with OMCs from wild-type strain H44/76 (dotted line) and its
LPS mutant (solid line), and B7-1 and B7-2 surface
expression was compared with results from medium-incubated cells
(filled histogram). (A) Analysis of inducible expression of
costimulatory cell surface molecule B7-2. (B) Analysis of the level of
expression of the B7-1 cell surface molecule. Both analyses were
performed by flow cytometry.
|
|
 |
DISCUSSION |
The purpose of this study was to examine the immunogenicity of
PorA and PorB meningococcal porins in conjunction with LPS in order to
evaluate their potential as vaccine candidates and to determine the
necessity of LPS for the induction of antiporin immune responses. Both
the porins and LPS have been investigated individually as plausible
antineisserial vaccine candidates in the past (5, 25, 32, 37,
38). Results from the current study revealed that the presence
of LPS in conjunction with PorB on the bacterial cell surface affects
the anti-PorB humoral immune response mounted by mice. However, it is
important to note that the presence of LPS is not essential for evoking
an anti-Por response, as demonstrated by the elevated levels of
anti-PorB IgG in mice immunized with the LPS-negative mutant (>3
µg/ml) (Table 2). This is consistent with the initial observation
made in Salmonella enterica serovar Typhosa regarding the
ability of LPS to function as an adjuvant (16). An
immunomodulatory role of LPS on the anti-PorA humoral response evoked
by OMCs from N. meningitidis was observed by Steeghs et al.
(29), especially with regard to the generation of
bactericidal anti-PorA antibodies. However, they did not investigate
the anti-PorB response, accounting for their conclusion that LPS is
essential for an antiporin humoral response, which we have demonstrated
is not necessarily the case.
Interestingly, the anti-PorB response observed in this study is much
higher than the anti-PorA response in sera from mice immunized with
whole bacteria, which is a pattern similar to that observed in patients
with meningococcal disease (14, 15, 17). On the other
hand, the anti-PorA and anti-PorB IgG levels obtained in mice immunized
with purified porins were very similar. These results could be
explained by the presence of higher amounts of PorB than of PorA on the
bacterial cell surface (26) and/or by PorB's possible
immunodominance over PorA when the two proteins are present together on
intact meningococci. However, when outer membrane vesicle vaccines are
used, the immunogenicity of PorA has been shown to be much greater than
that of PorB (33, 34), possibly due to an alteration in
the structure of PorB during the synthesis of the outer membrane
vesicle vaccine, diminishing its immunogenicity.
The augmentation of the antiporin immune response by LPS appears not to
be due to an alteration in the stoichiometric presentation of the
porins. This was demonstrated by the following findings: (i) anti-PorB
IgG levels induced by either the wild-type or LPS-negative meningococcal strain were similar in the LPS hyporesponsive C3H/HeJ mice, and (ii) the anti-PorB IgG levels induced by the wild-type H44/76
strain were 10-fold higher in LPS-responsive C3H/HeOuJ mice's sera
than in sera from the LPS-hyporesponsive mice. The effect on immune
response due to an altered structure of PorB discussed in point ii can
be ruled out because the observed IgG concentrations against the
LPS-positive strain are similar to those against the LPS
mutant in mice that do not respond to LPS.
In the present study we also demonstrate that the expression of B7-2 on
the surface of B cells stimulated by PorB does not require the presence
of LPS (Fig. 1). Stimulation of B cells isolated from either C3H/HeJ or
C3H/HeOuJ mice with OMC preparations from either of the two bacterial
strains induces similar levels of B7-2 expression. Inducible B7-2
levels are slightly higher in C3H/HeOuJ B cells incubated with OMCs
from the wild-type bacterial strain. This result is consistent with a
previously reported observation (38) that PorB by itself
is able to induce the expression of costimulatory B7-2 molecules in B
cells isolated from either the C3H/HeJ or the C3H/HeOuJ mice. Also,
this induction of B7-2 molecules by PorB in B cells from either murine
strain is not significantly affected by the presence of trace amounts
of LPS. Here we observe that the presence of LPS in amounts that
naturally coexist with PorB on bacterial cell surfaces does not
modulate the immunopotentiating effect of PorB (as deduced from the
expression of similar levels of B7-2 on B cells isolated from either
murine strain when incubated with OMCs prepared from the two bacterial strains).
 |
ACKNOWLEDGMENTS |
This research was supported by the National Institutes of Health
(AI-40944) and the World Health Organization Global Program in
Vaccines/Vaccine Research and Development.
We gratefully acknowledge the gift of the LPS-negative H44/76 strain of
N. meningitidis from Peter van der Ley, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Boston University School of Medicine, Evans
Biomedical Research Center, 650 Albany St., Boston, MA 02118. Phone:
(617) 414-4394. Fax: (617) 414-4391. E-mail:
lwetzler{at}bu.edu.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Andersson, J.,
O. S. Sjoberg, and G. Mollen.
1972.
Induction of immunoglobulin and antibody synthesis in vitro by lipopolysaccharides.
Eur. J. Immunol.
2:349[Medline].
|
| 2.
|
Benz, R.
1994.
Permeation of hydrophilic solutes through mitochondrial outer membranes: review on mitochondrial porins.
Biochim. Biophys. Acta
1197:167-196[Medline].
|
| 3.
|
Bjune, G.,
E. A. Hoiby,
J. K. Gronnesby,
O. Arnesen,
J. H. Fredriksen,
A. Halstensen,
E. Holten,
A.-K. Lindbak,
H. Nokleby,
E. Rosenquist,
L. K. Solberg,
O. Closs,
J. Eng,
L. O. Froholm,
A. Lystad,
L. S. Bakketeig, and B. Hareide.
1991.
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
Lancet
338:1093-1096[CrossRef][Medline].
|
| 4.
|
Blake, M. S., and E. C. Gotschlich.
1986.
Functional and immunological properties of pathogenic neisserial surface proteins, p. 377-400.
In
M. Inouye (ed.), Bacterial outer membranes as model systems. John Wiley & Sons, Inc., New York, N.Y.
|
| 5.
|
Blake, M. S., and L. M. Wetzler.
1995.
Vaccines for gonorrhea: where are we on the curve?
Trends Microbiol.
3:469-474[CrossRef][Medline].
|
| 6.
|
Centers for Disease Control and Prevention.
1999.
Summary of notifiable diseases, United States, 1998.
Morb. Mortal. Wkly. Rep.
47:ii-92[Medline].
|
| 7.
|
Coligan, J. E.,
A. M. Kruisbeek,
D. H. Margulies,
E. M. Shevach, and W. Strober (ed.).
1994.
Current protocols in immunology, p. 5.0.1-5.8.8.
John Wiley & Sons, Inc., New York, N.Y.
|
| 8.
|
Diaz, R. J., and I. M. Outschoorn.
1994.
Current status of meningococcal group B vaccine candidates: capsular or noncapsular?
Clin. Microbiol. Rev.
7:559-575[Abstract/Free Full Text].
|
| 9.
|
Donnelly, J. J.,
R. R. Deck, and M. A. Liu.
1990.
Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein vaccine.
J. Immunol.
145:3071-3079[Abstract].
|
| 10.
|
Finne, J.,
M. Leinonen, and P. H. Makela.
1983.
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.
Lancet
ii:355-357.
|
| 11.
|
Fusco, P. C.,
F. Michon,
M. Laude-Sharp,
C. A. Minetti,
C. H. Huang,
I. Heron, and M. S. Blake.
1998.
Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine.
Vaccine
16:1842-1849[CrossRef][Medline].
|
| 12.
|
Fusco, P. C.,
F. Michon,
J. Y. Tai, and M. S. Blake.
1997.
Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates.
J. Infect Dis.
175:364-372[Medline].
|
| 13.
|
Griffiss, J. M.,
R. Yamasaki,
M. Estabrook, and J. J. Kim.
1991.
Meningococcal molecular mimicry and the search for an ideal vaccine.
Trans. R. Soc. Trop. Med. Hyg.
85(Suppl. 1):32-36.
|
| 14.
|
Guttormsen, H. K.,
L. M. Wetzler, and A. Naess.
1993.
Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.
Infect. Immun.
61:4734-4742[Abstract/Free Full Text].
|
| 15.
|
Guttormsen, H. K.,
L. M. Wetzler, and C. O. Solberg.
1994.
Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease.
Infect. Immun.
62:1437-1443[Abstract/Free Full Text].
|
| 16.
|
Johnson, A. G.,
G. Gaines, and M. Landy.
1956.
Studies on the O antigen of Salmonella typhosa: V. Enhancement of antibody response to protein antigen by the purified lipopolysaccharide.
J. Exp. Med.
103:225-230[Abstract].
|
| 17.
|
Lehmann, A. K.,
A. Halstensen,
I. S. Aaberge,
J. Holst,
T. E. Michaelsen,
S. Sornes,
L. M. Wetzler, and H. Guttormsen.
1999.
Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.
Infect. Immun.
67:2552-2560[Abstract/Free Full Text].
|
| 18.
|
Lepow, M. L.,
J. Beeler,
M. Randolph,
J. S. Samuelson, and W. A. Hankins.
1986.
Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children.
J. Infect. Dis.
154:1033-1036[Medline].
|
| 19.
|
Lowell, G. H.
1990.
Proteosomes, hydrophobic anchors, iscoms, and liposomes for improved presentation of peptides and protein vaccines, p. 141-160.
In
G. C. Woodrow, and M. M. Levine (ed.), New generation vaccines. Marcel Dekker, Inc, New York, N.Y.
|
| 20.
|
Lowell, G. H.,
W. R. Ballou,
L. F. Smith,
R. A. Wirtz,
W. D. Zollinger, and W. T. Hockmeyer.
1988.
Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.
Science
240:800-802[Abstract/Free Full Text].
|
| 21.
|
Lowell, G. H.,
L. F. Smith,
R. C. Seid, and W. D. Zollinger.
1988.
Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvant.
J. Exp. Med.
167:658-663[Abstract/Free Full Text].
|
| 22.
|
Mackinnon, F. G.,
Y. Ho,
M. S. Blake,
F. Michon,
A. Chandraker,
M. H. Sayegh, and L. M. Wetzler.
1999.
The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin.
J. Infect. Dis.
180:755-761[CrossRef][Medline].
|
| 23.
|
Morse, S. A.,
S. Stein, and J. Hines.
1974.
Glucose metabolism in Neisseria gonorrhoeae.
J. Bacteriol.
120:707-714.
|
| 24.
|
Poltorak, A.,
X. He,
I. Smirnova,
M. Y. Liu,
C. V. Huffel,
X. Du,
D. Birdwell,
E. Alejos,
M. Silva,
C. Galanos,
M. Freudenberg,
P. Ricciardi-Castagnoli,
B. Layton, and B. Beutler.
1998.
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
Science
282:2085-2088[Abstract/Free Full Text].
|
| 25.
|
Poolman, J. T.
1995.
Development of a meningococcal vaccine.
Infect. Agents Dis.
4:13-28[Medline].
|
| 26.
|
Poolman, J. T., and H. C. Zanen.
1980.
Detection of antibody activity in human sera against meningococcal cell wall antigens using a gel-immuno-radio-assay (GIRA).
FEMS Microbiol. Lett.
7:293-296[CrossRef].
|
| 27.
|
Scholten, R. J.,
H. A. Bijlmer,
J. T. Poolman,
B. Kuipers,
D. A. Caugant,
L. Van Alphen,
J. Dankert, and H. A. Valkenburg.
1993.
Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis.
Clin. Infect. Dis.
16:237-246[Medline].
|
| 28.
|
Steeghs, L.,
R. den Hartog,
A. den Boer,
B. Zomer,
P. Roholl, and P. van der Ley.
1998.
Meningitis bacterium is viable without endotoxin.
Nature
392:449-450[CrossRef][Medline].
|
| 29.
|
Steeghs, L.,
B. Kuipers,
H. J. Hamstra,
G. Kersten,
L. Van Alphen, and P. van der Ley.
1999.
Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.
Infect. Immun.
67:4988-4993[Abstract/Free Full Text].
|
| 30.
|
Tsai, C. M., and C. E. Frasch.
1982.
A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.
Anal. Biochem.
119:115-119[CrossRef][Medline].
|
| 31.
|
van der Ley, P.,
J. E. Heckels,
M. Virji,
P. Hoogerhout, and J. T. Poolman.
1991.
Topology of outer membrane porins in pathogenic Neisseria spp.
Infect. Immun.
59:2963-2971[Abstract/Free Full Text].
|
| 32.
|
Verheul, A. F.,
H. Snippe, and J. T. Poolman.
1993.
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.
Microbiol. Rev.
57:34-49[Abstract/Free Full Text].
|
| 33.
|
Wedege, E, and L. O. Froholm.
1986.
Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.
Infect. Immun.
51:571-578[Abstract/Free Full Text].
|
| 34.
|
Wedege, E.,
E. A. Hoiby,
E. Rosenqvist, and G. Bjune.
1998.
Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.
Infect. Immun.
66:3223-3231[Abstract/Free Full Text].
|
| 35.
|
Wetzler, L. M.
1994.
Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines.
Ann. N. Y. Acad. Sci.
730:367-370[CrossRef][Medline].
|
| 36.
|
Wetzler, L. M.,
M. S. Blake,
K. Barry, and E. C. Gotschlich.
1992.
Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes and blebs isolated from rmp deletion mutants.
J. Infect. Dis.
166:551-555[Medline].
|
| 37.
|
Wetzler, L. M.,
M. S. Blake, and E. C. Gotschlich.
1988.
Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations.
J. Exp. Med.
168:1883-1897[Abstract/Free Full Text].
|
| 38.
|
Wetzler, L. M.,
Y. Ho, and H. Reiser.
1996.
Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate.
J. Exp. Med.
183:1151-1159[Abstract/Free Full Text].
|
| 39.
|
Zollinger, W. D.
1990.
New and improved vaccines against meningococcal disease, p. 325-348.
In
G. C. Woodrow, and M. M. Levine (ed.), New generation vaccines. Marcel Dekker, Inc, New York, N.Y.
|
Infection and Immunity, August 2001, p. 5031-5036, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5031-5036.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
MacLeod, H., Bhasin, N., Wetzler, L. M.
(2008). Role of Protein Tyrosine Kinase and Erk1/2 Activities in the Toll-Like Receptor 2-Induced Cellular Activation of Murine B Cells by Neisserial Porin. CVI
15: 630-637
[Abstract]
[Full Text]
-
Massari, P., Henneke, P., Ho, Y., Latz, E., Golenbock, D. T., Wetzler, L. M.
(2002). Cutting Edge: Immune Stimulation by Neisserial Porins Is Toll-Like Receptor 2 and MyD88 Dependent. J. Immunol.
168: 1533-1537
[Abstract]
[Full Text]